Department of Obstetrics and Gynaecology, Peking University First Hospital, Beijing 100034, China;
Department of Obstetrics and Gynaecology, Beijing Hospital, Beijing 100730, China;
Department of Obstetrics and Gynaecology, General Hospital of the PLA, Beijing 100853, China;
Department of Obstetrics and Gynaecology, Peking University First Hospital, Beijing 100034, China;
Department of Obstetrics and Gynaecology, Beijing Hospital, Beijing 100730, China;
Department of Obstetrics and Gynaecology, General Hospital of the PLA, Beijing 100853, China;
Department of Obstetrics and Gynaecology, Peking University First Hospital, Beijing 100034, China;
Department of Obstetrics and Gynaecology, Beijing Hospital, Beijing 100730, China;
Department of Obstetrics and Gynaecology, General Hospital of the PLA, Beijing 100853, China;
Eli Lilly & Company, Indianapolis, Indiana, USA;
Eli Lilly & Company, Indianapolis, Indiana, USA;
Eli Lilly & Company, Indianapolis, Indiana, USA;
Department of Obstetrics and Gynaecology, General Hospital of the PLA, Beijing 100853, China;
raloxifene; bone mineral density; metabolism; lipids; postmenopause;